ICU Stock Analysis: Buy, Sell, or Hold?
ICU - SeaStar Medical Holding Corporation Common Stock
$4.49
-0.37 (-7.61%)
▼
5d:
+2.75%
30d:
+10.59%
90d:
+81.05%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 13, 2026
3d
Get Alerted When ICU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ICU this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ICU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ICU shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ICU is currently trading at $4.49, which is considered slightly high relative to its 30-day fair value range of $3.83 to $4.51.
Technical Outlook: Technically, ICU is in a strong uptrend. Immediate support is located at $3.72, while resistance sits at $5.10. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: ICU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+100.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ICU is in a strong uptrend. Immediate support is located at $3.72, while resistance sits at $5.10. Short-term momentum is weak, with the stock down 7.6% recently.
Market Sentiment: ICU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+100.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.83 -
$4.51
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.6%)
- BULLISH: Trading 100.4% below Wall St target ($9.00)
Trading Range Analysis
30-Day Trading Range
$3.83 -
$4.51
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.72
Resistance Level
$5.10
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.17
Wall Street Target
$9.00
(+100.4%)
Revenue Growth (YoY)
526.9%
Share & Embed Analysis
Last updated: May 08, 2026 9:48 PM ET
Data refreshes hourly during market hours. Next update: 10:48 PM
Data refreshes hourly during market hours. Next update: 10:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICU showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jennifer A Baird
BUY
420 shares
2025-12-19
Michael Messinger
BUY
1450 shares
2025-12-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$408 | 58 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$230 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 58 HOLD |
